There is a need for therapies for patients with low eGFR. Daniël van Raalte discusses whether GLP-1RA therapy can provide benefit for patients with T2DM and CKD. With question to test your knowledge.
Subtitles: English, French, German & more
This lecture by Daniël van Raalte was part of the EBAC-accredited symposium "GLP-1RA in DKD: A new preventive challenge" held during the virtual ERA EDTA 2021 congress.
Dr. Daniël van Raalte is internist-endocrinologist in Amsterdam UMC, locatie VUmc, Amsterdam, The Netherlands.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant from Novo Nordisk A/S.The content is aimed for medical professionals. To view this item member registration is needed. Register for free to get unlimited access to our educational resources.
Sorry, this content is unavailable in your country.The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
- GLP-1RA in DKD: A new preventive challengeWhere do GLP-1RA fit in in current and future management of CKD?
Frederik Persson, MD
- GLP-1RA in DKD: A new preventive challengePrevention strategies in patients with CKD and T2DM
Ofri Mosenzon, MD